Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1492658/000149265820000003/a10kwmgi-12292019.htm
November 2020
April 2020
April 2020
November 2019
August 2019
June 2019
May 2019
February 2019
February 2019
February 2019
Document and Entity Information Document - USD ($) $ in Billions | 12 Months Ended | ||
---|---|---|---|
Dec. 29, 2019 | Feb. 20, 2020 | Jun. 30, 2019 | |
Cover page. | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 29, 2019 | ||
Document Transition Report | false | ||
Entity File Number | 001-35065 | ||
Entity Registrant Name | WRIGHT MEDICAL GROUP N.V. | ||
Entity Incorporation, State or Country Code | P7 | ||
Entity Tax Identification Number | 98-0509600 | ||
Entity Address, Address Line One | Prins Bernhardplein 200 | ||
Entity Address, Address Line Two | 1097 JB | ||
Entity Address, City or Town | Amsterdam, | ||
Entity Address, Country | NL | ||
Entity Address, Postal Zip Code | None | ||
City Area Code | 20 | ||
Local Phone Number | 521 4777 | ||
Title of 12(b) Security | Ordinary shares, par value €0.03 per share | ||
Trading Symbol | WMGI | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 3.7 | ||
Entity Common Stock, Shares Outstanding | 128,733,780 | ||
Documents Incorporated by Reference | Part III of this Annual Report on Form 10-K incorporates by reference certain portions of the registrant’s definitive proxy statement for its Extraordinary General Meeting of Shareholders (“Proxy Statement”) anticipated to be filed with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year covered by this report. Except as expressly incorporated by reference, the registrant’s Proxy Statement shall not be deemed to be part of this report. | ||
Entity Central Index Key | 0001492658 | ||
Current Fiscal Year End Date | --12-29 | ||
Document Fiscal Year Focus | 2019 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1492658/000149265820000003/a10kwmgi-12292019.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Wright Medical Group N.V..
Wright Medical Group N.V.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:
Rating
Learn More
This decrease in net loss from continuing operations was primarily driven by a decrease in other expense, net as 2018 included a $39.9 million charge for the write-off of unamortized deferred financing fees and debt discount associated with the extinguishment of $400.0 million of the 2020 Notes and a $35.9 million loss for the net mark-to-market adjustments on our derivative assets and liabilities.
Non-GAAP organic international lower extremities sales decreased 1.5%, mostly due to a $2.4 million unfavorable impact from foreign currency exchange rates (a 4 percentage point unfavorable impact to international lower extremities sales growth rate).
Our international biologics net sales decreased 14.5% to $22.0 million in 2019 from $25.8 million in 2018, due to timing of sales to stocking distributors and a $0.7 million unfavorable impact from foreign currency exchange rates (a 3 percentage point unfavorable impact to international biologics sales growth rate).
This increase was driven by net sales volume growth of AUGMENT Injectable, which launched at the end of the second quarter of 2018 after receiving FDA approval, and in our core biologics products.
This increase was driven by net sales volume growth in our core biologics products and AUGMENT Injectable, which launched at the end of the second quarter of 2018 after receiving FDA approval.
The increase in cash provided...Read more
We also had a $4.8...Read more
We also had a $3.1...Read more
We believe we have significant...Read more
This 0.9% increase was primarily...Read more
Our U.S. biologics net sales...Read more
Our U.S. biologics net sales...Read more
Our cost of sales and...Read more
In 2019, other expense, net,...Read more
We believe that non-GAAP financial...Read more
Our non-GAAP financial measures are...Read more
Our international net sales increased...Read more
We intend to continue to...Read more
Net sales increased 10.1% totaling...Read more
We received proceeds of approximately...Read more
We received proceeds of approximately...Read more
We believe our U.S. lower...Read more
We also have significant operations...Read more
This growth was primarily driven...Read more
Sales increased by a combined...Read more
U.S. net sales totaled $706.3...Read more
U.S. net sales totaled $623.5...Read more
This increase was primarily due...Read more
Accordingly, the calculation of our...Read more
Cash used in discontinued operations...Read more
Our cost of sales as...Read more
These increases were offset by...Read more
These increases were partially offset...Read more
Supported by compelling clinical performance...Read more
Our U.S. net sales increased...Read more
Net sales of our U.S....Read more
Net sales of our International...Read more
Net sales of our U.S....Read more
Net sales of our International...Read more
Our U.S. upper extremities net...Read more
Our U.S. upper extremities net...Read more
The growth of our business...Read more
Further, we believe our December...Read more
These sales representatives and independent...Read more
Sales increased primarily due to...Read more
Our international upper extremities net...Read more
Our international biologics net sales...Read more
Our international upper extremities net...Read more
Additionally, the impact from the...Read more
On February 25, 2019, we...Read more
We believe a more active...Read more
Based on intangible assets held...Read more
All outstanding loans under the...Read more
The ongoing launch of our...Read more
These increases to both net...Read more
Operating income of our U.S....Read more
Operating income of our U.S....Read more
We do not expect that...Read more
This increase was offset by...Read more
Charges associated with amortization of...Read more
Charges associated with amortization of...Read more
We are committed to delivering...Read more
Our 2019 net tax provision...Read more
Research and development costs remained...Read more
Our 2019 cost of sales...Read more
Increased interest expense was driven...Read more
We, as well as other...Read more
This growth was driven by...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Wright Medical Group N.V. provided additional information to their SEC Filing as exhibits
Ticker: WMGI
CIK: 1492658
Form Type: 10-K Annual Report
Accession Number: 0001492658-20-000003
Submitted to the SEC: Mon Feb 24 2020 5:04:55 PM EST
Accepted by the SEC: Mon Feb 24 2020
Period: Sunday, December 29, 2019
Industry: Orthopedic Prosthetic And Surgical Appliances And Supplies